Literature DB >> 3936717

Cross-over study of the pharmacokinetics of cefonicid administered intravenously or intramuscularly to healthy adult humans.

J B Fourtillan, A Leroy, M A Lefebvre, G Humbert, J P Fillastre, G Reumont, N Ramis.   

Abstract

The pharmacokinetics of cefonicid were investigated in eight healthy adults. A one-gram dose was administered either intramuscularly or intravenously in a cross-over design study. Mean peak cefonicid plasma concentrations of 186 to 204 mcg/ml and 88 to 123 mcg/ml were achieved after intravenous and intramuscular injection, respectively, with elimination half-lives of 4.9 h and 5.3 h. Cefonicid concentrations were measured by both microbiological (M.A.) and high-performance liquid chromatography (HPLC) assays. Results were quite similar with the two techniques, except for the urinary recovery of cefonicid in the first 24 hours (83% of the dose with MA - vs 53% with HPLC method). The apparent volume of distribution (Vd area) was 0.18 1/kg; the total body clearance (CT) and the renal clearance (CR) were 24-26 ml/min and 15-19 ml/min, respectively. The kinetic data of cefonicid were not significantly different for the two routes of administration. A one-gram i.v. or i.m. cefonicid dose produced high and prolonged plasma concentrations with a longer half-life than obtained with commonly used cephalosporins.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3936717     DOI: 10.1007/bf03189746

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  6 in total

1.  IGPHARM: interactive graphic package for pharmacokinetic analysis.

Authors:  C Gomeni; R Gomeni
Journal:  Comput Biomed Res       Date:  1978-08

2.  Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin.

Authors:  S L Barriere; G J Hatheway; J G Gambertoglio; E T Lin; J E Conte
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

3.  SK&F 75073, new parenteral broad-spectrum cephalosporin with high and prolonged serum levels.

Authors:  P Actor; J V Uri; I Zajac; J R Guarini; L Phillips; D H Pitkin; D A Berges; G L Dunn; J R Hoover; J A Weisbach
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

4.  Cefonicid: a stable beta-lactamase inhibitor.

Authors:  R J Mehta; D J Newman; B A Bowie; C H Nash; P Actor
Journal:  J Antibiot (Tokyo)       Date:  1981-02       Impact factor: 2.649

5.  Cefonicid kinetics in subjects with normal and impaired renal function.

Authors:  A D Blair; B M Maxwell; S C Forland; L Jacob; R E Cutler
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

6.  Kinetics and renal handling of cefonicid.

Authors:  D Pitkin; J Dubb; P Actor; F Alexander; S Ehrlich; R Familiar; R Stote
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

  6 in total
  1 in total

Review 1.  Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  E Saltiel; R N Brogden
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.